South Korean bioventures felt a sharp deterioration in investor sentiment in the financing market in the second quarter, with venture capital financing declining and only one initial public offering launched during the period.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?